Anchem Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 M
- Revenue Growth 72.16%
- Profit Growth 146.73%
- Ebitda 110.91%
- Net Worth 110.12%
- Total Assets 9.65%
About Anchem Laboratories
Anchem Laboratories Private Limited (ALPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 April 2018 (Six years and nine months 30 days old ). Its registered office is in Jodhpur, Rajasthan, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.00 M.
Ashok Gaur and Snehlata Gaur serve as directors at the Company.
Company Details
- Location
Jodhpur, Rajasthan, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909RJ2018PTC061007
- Company No.
061007
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Apr 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Anchem Laboratories?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashok Gaur  | Director | 24-Apr-2018 | Current |
| Snehlata Gaur | Director | 24-Aug-2018 | Current |
Financial Performance of Anchem Laboratories.
Anchem Laboratories Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 72.16% increase. The company also saw a substantial improvement in profitability, with a 146.73% increase in profit. The company's net worth Soared by an impressive increase of 110.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Anchem Laboratories?
Unlock access to Anchem Laboratories's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Apr 2019 | Others | ₹1.00 M | Open |
How Many Employees Work at Anchem Laboratories?
Unlock and access historical data on people associated with Anchem Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Anchem Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Anchem Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
